Oklahoma § 63-7321 Health benefit plans to allow coverage for drugs to treat

Oklahoma Statutes

§ 63-7321 — Health benefit plans to allow coverage for drugs to treat

Oklahoma § 63-7321

Title 63Public Health And Safety

This text of Oklahoma § 63-7321 (Health benefit plans to allow coverage for drugs to treat) is published on Counsel Stack Legal Research, covering Oklahoma primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Okla. Stat. tit. 63, § 63-7321 (2026).

Text

advanced metastatic cancer and associated conditions without proving step therapy.

A.A health benefit plan that provides coverage for advanced metastatic cancer and associated conditions may not require, before the health benefit plan provides coverage of a prescription drug approved by the United States Food and Drug Administration, that the enrollee: 1. Fails to successfully respond to a different drug; or 2. Proves a history of failure of a different drug.

B.This section applies only to a drug, the use of which is: 1. Consistent with best practices for the treatment of advanced metastatic cancer or an associated condition; 2. Supported by peer-reviewed, evidence-based literature; and 3. Approved by the United States Food and Drug Administration.

Free access — add to your briefcase to read the full text and ask questions with AI

advanced metastatic cancer and associated conditions without proving step therapy. A. A health benefit plan that provides coverage for advanced metastatic cancer and associated conditions may not require, before the health benefit plan provides coverage of a prescription drug approved by the United States Food and Drug Administration, that the enrollee: 1. Fails to successfully respond to a different drug; or 2. Proves a history of failure of a different drug. B. This section applies only to a drug, the use of which is: 1. Consistent with best practices for the treatment of advanced metastatic cancer or an associated condition; 2. Supported by peer-reviewed, evidence-based literature; and 3. Approved by the United States Food and Drug Administration.